<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03886701</url>
  </required_header>
  <id_info>
    <org_study_id>12690</org_study_id>
    <nct_id>NCT03886701</nct_id>
  </id_info>
  <brief_title>Doravirine, Rifapentine and Isoniazid Interaction</brief_title>
  <acronym>DORIIS</acronym>
  <official_title>A Phase 1, Open-Label, Fixed-Sequence, Drug Interaction Study to Investigate the Effect of Once-Weekly Rifapentine and Isoniazid on the Pharmacokinetics of Steady-State Doravirine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Walter K. Kraft</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Thomas Jefferson University</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Drug therapy for persons living with human immunodeficiency virus (HIV) or acquired
      immunodeficiency syndrome (AIDS) co-infected with latent tuberculosis infection (LTBI) is
      complex. Anti-tuberculosis drugs used to treat LTBI often induce drug metabolizing enzymes
      that share the same metabolic pathway as antiretroviral drugs used for those living with
      HIV/AIDS. This study evaluates the drug-drug interaction (DDI) potential of an antiretroviral
      drug when co-administered with a common anti-tuberculosis regimen of drugs.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rifapentine (RPT) and isoniazid (INH) given once weekly for 12 weeks is commonly used for
      treating LTBI in adults. For people living with HIV-1, the risks of LTBI is increased.
      Individuals living with HIV-1 are often on chronic antiretroviral drugs that prevent
      immunodeficiency and complications associated with infection. Unfortunately, antiretroviral
      drugs are subject to many DDIs especially with RPT which induces drug clearing enzymes.

      Doravirine (DOR) is a newly approved non-nucleoside reverse transcriptase inhibitor indicated
      for the treatment of HIV-1 infection. Because RPT induces the metabolic pathway in which DOR
      is removed, there is concern that taking both concomitantly will result in an unwanted DDI
      leading to reduced DOR concentrations in the blood. Reduced levels will result in loss of
      efficacy for the drug and therefore not provide adequate viral suppression in those living
      with HIV. This study investigates the DDI potential of the once weekly regimen RPT and INH
      together with DOR in healthy volunteers.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 22, 2019</start_date>
  <completion_date type="Actual">May 20, 2019</completion_date>
  <primary_completion_date type="Actual">May 20, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Doravirine Maximum Concentration (Cmax)</measure>
    <time_frame>Day 4 and 21 (Period 1 and 2): 0, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96 hours post-dose</time_frame>
    <description>Doravirine maximum observed concentration during the dosing interval</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Doravirine Area Under the Plasma Concentration Versus Time Curve From 0 to 12 Hours (AUC0-12)</measure>
    <time_frame>Day 4 and 21 (Period 1 and 2): 0, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96 hours post-dose</time_frame>
    <description>Doravirine area under the plasma-concentration time curve derived from plasma sampling during one dosing interval</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Doravirine Oral Clearance (CL/F)</measure>
    <time_frame>Day 4 and 21 (Period 1 and 2): 0, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96 hours post-dose</time_frame>
    <description>Doravirine apparent oral clearance derived from plasma sampling</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Event</measure>
    <time_frame>Days 1-24 post-dose (period 1 and 2) and 31-34 post-dose (post-study)</time_frame>
    <description>Safety and tolerability</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Latent Tuberculosis</condition>
  <condition>Human Immunodeficiency Virus</condition>
  <condition>Rifamycins Causing Adverse Effects in Therapeutic Use</condition>
  <condition>Drug Interaction Potentiation</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: DOR twice-daily alone (Study days 1-4) and Period 2: DOR twice-daily with RPT and INH once-weekly (Study days 7-21)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doravirine (DOR)</intervention_name>
    <description>Non-nucleoside reverse transcriptase inhibitor indicated for the treatment of HIV-1 infection in adults in combination with other antiretroviral agents.</description>
    <arm_group_label>Experimental</arm_group_label>
    <other_name>Pifeltro</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifapentine (RPT)</intervention_name>
    <description>Rifamycin anti-tuberculosis agent indicated for the treatment of latent and active tuberculosis infection.</description>
    <arm_group_label>Experimental</arm_group_label>
    <other_name>Priftin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isoniazid (INH)</intervention_name>
    <description>Anti-tuberculosis agent indicated for the treatment of latent and active tuberculosis infection.</description>
    <arm_group_label>Experimental</arm_group_label>
    <other_name>Generic (various)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy male or female between 18-60 years old at the time of screening.

          2. Have a Body Mass Index (BMI) &gt; 19 and &lt; 33.

          3. Weigh &gt; 45 kg but &lt; 120 kg.

          4. Non-smoker (tobacco or electronic cigarettes).

          5. Negative QuantiFERON-TB Gold at screening.

          6. Subjects who agree to abstain from alcohol consumption throughout the duration of the
             study.

          7. Female subjects of childbearing potential must demonstrate a urine beta-hCG consistent
             with non-pregnancy at the time of the screening visit and agree to the use (and/or
             have their partner use) of an acceptable method of birth-control at initial screening,
             during the time of the trial and until two weeks after the last dose of drug following
             the last treatment period.

          8. Evidence of a personally signed and dated informed consent document indicating that
             the subject has been informed of all pertinent aspects of the study.

        Exclusion Criteria:

          1. History of clinically significant endocrine, gastrointestinal, cardiovascular,
             hematological, hepatic, immunological, renal, respiratory, genitourinary,
             dermatologic, psychiatric abnormalities or neurological (including stroke and chronic
             seizure) diseases.

          2. &gt;500 mL blood or plasma donation in the 6 weeks prior to study start

          3. Known anaphylactic or severe systemic reactions to any components of doravirine,
             rifapentine, isoniazid or pyridoxine.

          4. Positive HIV, Hepatitis B or Hepatitis C virus. Evidence of prior Hepatitis B
             infection and immunity is not exclusionary.

          5. Latent or active tuberculosis infection. Documented prior fully treated latent
             tuberculosis is not exclusionary.

          6. Females who are postpartum &lt; 12 months.

          7. Current drug or alcohol abuse.

          8. Received study drug in another study within 4 weeks or within 5 half-lives, which ever
             occurring first, before first anticipated dose of study drug in this study.

          9. Unable to refrain from use of over-the-counter, prescription (unless determined
             appropriate by the investigator), herbal or natural products, vitamins or supplements,
             or grapefruit juice/grapefruit products.

         10. Any clinical significant findings on lab, ECG or physical exam at screening.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Walter K Kraft, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sidney Kimmel Medical College at Thomas Jefferson University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Thomas Jefferson University Clinical Research Unit</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 12, 2019</study_first_submitted>
  <study_first_submitted_qc>March 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 22, 2019</study_first_posted>
  <results_first_submitted>February 13, 2020</results_first_submitted>
  <results_first_submitted_qc>February 13, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">March 3, 2020</results_first_posted>
  <last_update_submitted>March 16, 2020</last_update_submitted>
  <last_update_submitted_qc>March 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Thomas Jefferson University</investigator_affiliation>
    <investigator_full_name>Walter K. Kraft</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Drug-drug interaction</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Non-nucleoside reverse transcriptase inhibitor</keyword>
  <keyword>NNRTI</keyword>
  <keyword>LTBI</keyword>
  <keyword>Antimycobacterial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Latent Tuberculosis</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Isoniazid</mesh_term>
    <mesh_term>Rifapentine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 17, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/01/NCT03886701/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Study Particpants</title>
          <description>Eleven healthy volunteers enrolled into the study. For period 1 (study days 1-4), participants will be given doravirine 100mg oral tablets dosed twice-daily on study days 1-4. For period 2 (study days 7-21), oral 100mg doravirine will be dosed twice-daily. Weight-based rifapentine and isoniazid (as recommended by the CDC) will be given orally once-weekly on study days 7, 14, and 21.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1: Study Days 1-4</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 2: Study Days 7-21</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Study Particpants</title>
          <description>Eleven healthy volunteers enrolled into the study.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50" lower_limit="27" upper_limit="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>Kilogram</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="92.9" spread="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Doravirine Maximum Concentration (Cmax)</title>
        <description>Doravirine maximum observed concentration during the dosing interval</description>
        <time_frame>Day 4 and 21 (Period 1 and 2): 0, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96 hours post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Period 1</title>
            <description>DOR twice-daily alone (Study days 1-4)
Doravirine (DOR): Non-nucleoside reverse transcriptase inhibitor indicated for the treatment of HIV-1 infection in adults in combination with other antiretroviral agents.
Rifapentine (RPT): Rifamycin anti-tuberculosis agent indicated for the treatment of latent and active tuberculosis infection.
Isoniazid (INH): Anti-tuberculosis agent indicated for the treatment of latent and active tuberculosis infection.</description>
          </group>
          <group group_id="O2">
            <title>Period 2</title>
            <description>DOR twice-daily with RPT/INH once-weekly (Study days 7-21)</description>
          </group>
        </group_list>
        <measure>
          <title>Doravirine Maximum Concentration (Cmax)</title>
          <description>Doravirine maximum observed concentration during the dosing interval</description>
          <units>ug/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" lower_limit="1.5" upper_limit="2"/>
                    <measurement group_id="O2" value="1.3" lower_limit="1.1" upper_limit="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Doravirine Area Under the Plasma Concentration Versus Time Curve From 0 to 12 Hours (AUC0-12)</title>
        <description>Doravirine area under the plasma-concentration time curve derived from plasma sampling during one dosing interval</description>
        <time_frame>Day 4 and 21 (Period 1 and 2): 0, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96 hours post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Period 1</title>
            <description>DOR twice-daily alone (Study days 1-4)
Doravirine (DOR): Non-nucleoside reverse transcriptase inhibitor indicated for the treatment of HIV-1 infection in adults in combination with other antiretroviral agents.
Rifapentine (RPT): Rifamycin anti-tuberculosis agent indicated for the treatment of latent and active tuberculosis infection.
Isoniazid (INH): Anti-tuberculosis agent indicated for the treatment of latent and active tuberculosis infection.</description>
          </group>
          <group group_id="O2">
            <title>Period 2</title>
            <description>DOR twice-daily with RPT/INH once-weekly (Study days 7-21)</description>
          </group>
        </group_list>
        <measure>
          <title>Doravirine Area Under the Plasma Concentration Versus Time Curve From 0 to 12 Hours (AUC0-12)</title>
          <description>Doravirine area under the plasma-concentration time curve derived from plasma sampling during one dosing interval</description>
          <units>hr x ug/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.3" lower_limit="14.9" upper_limit="20"/>
                    <measurement group_id="O2" value="12.3" lower_limit="10.4" upper_limit="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Doravirine Oral Clearance (CL/F)</title>
        <description>Doravirine apparent oral clearance derived from plasma sampling</description>
        <time_frame>Day 4 and 21 (Period 1 and 2): 0, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96 hours post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Period 1</title>
            <description>DOR twice-daily alone (Study days 1-4)
Doravirine (DOR): Non-nucleoside reverse transcriptase inhibitor indicated for the treatment of HIV-1 infection in adults in combination with other antiretroviral agents.
Rifapentine (RPT): Rifamycin anti-tuberculosis agent indicated for the treatment of latent and active tuberculosis infection.
Isoniazid (INH): Anti-tuberculosis agent indicated for the treatment of latent and active tuberculosis infection.</description>
          </group>
          <group group_id="O2">
            <title>Period 2</title>
            <description>DOR twice-daily with RPT/INH once-weekly (Study days 7-21)</description>
          </group>
        </group_list>
        <measure>
          <title>Doravirine Oral Clearance (CL/F)</title>
          <description>Doravirine apparent oral clearance derived from plasma sampling</description>
          <units>L/hr</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.9" spread="24"/>
                    <measurement group_id="O2" value="8.4" spread="26.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Event</title>
        <description>Safety and tolerability</description>
        <time_frame>Days 1-24 post-dose (period 1 and 2) and 31-34 post-dose (post-study)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Period 1</title>
            <description>DOR twice-daily alone (Study days 1-4)
Doravirine (DOR): Non-nucleoside reverse transcriptase inhibitor indicated for the treatment of HIV-1 infection in adults in combination with other antiretroviral agents.
Rifapentine (RPT): Rifamycin anti-tuberculosis agent indicated for the treatment of latent and active tuberculosis infection.
Isoniazid (INH): Anti-tuberculosis agent indicated for the treatment of latent and active tuberculosis infection.</description>
          </group>
          <group group_id="O2">
            <title>Period 2</title>
            <description>DOR twice-daily with RPT/INH once-weekly (Study days 7-21)</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Event</title>
          <description>Safety and tolerability</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Nausea/vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dysuria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Catheter site pain and redness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Daily for the duration of the study and 7-10 days post-study.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Period 1</title>
          <description>DOR twice-daily alone (Study days 1-4)
Doravirine (DOR): Non-nucleoside reverse transcriptase inhibitor indicated for the treatment of HIV-1 infection in adults in combination with other antiretroviral agents.
Rifapentine (RPT): Rifamycin anti-tuberculosis agent indicated for the treatment of latent and active tuberculosis infection.
Isoniazid (INH): Anti-tuberculosis agent indicated for the treatment of latent and active tuberculosis infection.</description>
        </group>
        <group group_id="E2">
          <title>Period 2</title>
          <description>DOR twice-daily with RPT/INH once-weekly (Study days 7-21)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea/vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Catheter site pain and redness</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Walter K. Kraft</name_or_title>
      <organization>Thomas Jefferson University</organization>
      <phone>215 955-9077</phone>
      <email>walter.kraft@jefferson.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

